Current Clinical Pharmacology
Title: Editorial [Hot Topic: Kidney Cancer: State of the Art in 2011 (Guest Editor: Ulka Vaishampayan)]
Volume: 6 Issue: 3
Author(s): Ulka Vaishampayan
Affiliation:
Export Options
About this article
Cite this article as:
Vaishampayan Ulka, Editorial [Hot Topic: Kidney Cancer: State of the Art in 2011 (Guest Editor: Ulka Vaishampayan)], Current Clinical Pharmacology 2011; 6 (3) . https://dx.doi.org/10.2174/157488411797189370
DOI https://dx.doi.org/10.2174/157488411797189370 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
15
Related Articles
-
Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Anticancer Drugs Designed by Mother Nature: Ancient Drugs but Modern Targets
Current Pharmaceutical Design Looking Beyond Inhibition of VEGF/mTOR: Emerging Targets for Renal Cell Carcinoma Drug Development
Current Clinical Pharmacology Effects and Role of Multikinase Inhibitors in Thyroid Cancer
Current Pharmaceutical Design Reproducibility of Volumetric Assessment of the Inner Ear Using Three Dimensional Reconstruction of the High Resolution MR Sequence
Current Medical Imaging Association of ATG7 Polymorphisms and Clear Cell Renal Cell Carcinoma Risk
Current Molecular Medicine Elucidation of Cellular Metabolism Via Metabolomics and Stable-Isotope Assisted Metabolomics
Current Pharmaceutical Biotechnology Schiff Bases and Complexes: A Review on Anti-Cancer Activity
Anti-Cancer Agents in Medicinal Chemistry Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Prediction and Analysis of Hub Genes in Renal Cell Carcinoma based on CFS Gene Selection Method Combined with Adaboost Algorithm
Medicinal Chemistry Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Bladder Cancer: A Simple Model Becomes Complex
Current Genomics Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Past, Present and Future of Targeted Therapy in Solid Tumors
Current Cancer Drug Targets Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Recurrence in Bladder Cancer: A Molecular Dead End?
Current Genomics